Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


AIDS 2020: Virtual – Rapid Audio Recap

July 6-10, 2020; Virtual
Hear insights from Chloe Orkin, MBChB, FRCP, MD, on some of the most important new data reported at AIDS 2020: Virtual, including the use of current ART regimens in principal populations, metabolic outcomes during ART, HIV and COVID-19, investigational ART strategies, and HIV prevention.
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Released: August 14, 2020

In this episode, Dr. Orkin discusses results from key studies reported at AIDS 2020: Virtual, with new data on the following hot topics: current ART in principal populations, including older patients and women who become pregnant; metabolic outcomes during ART; HIV and COVID-19; investigational ART strategies; and HIV prevention. The overview includes:

  • The ADVANCE trial comparing initial ART with DTG plus FTC/TAF, DTG plus FTC/TDF, or EFV/FTC/TDF
  • A pooled analysis of randomized trials evaluating a switch to BIC/FTC/TAF in patients 65 years of age or older with virologic suppression on their current ART
  • A Kaiser Permanente study of BMI changes over time following ART initiation
  • An analysis of the longitudinal prospective OPERA cohort that assessed weight change with switch from TDF to TAF
  • Metabolic changes with switch from 3- or 4-drug TAF-based ART to 2-drug DTG/3TC in the TANGO study
  • Updated findings from the Tsepamo birth surveillance study in Botswana evaluating the prevalence of neural tube defects by antiretroviral exposure during conception/pregnancy
  • A retrospective study of COVID-19 in people with HIV presenting at 5 New York City Emergency Departments from March 2 to April 15, 2020
  • An analysis of protocol-defined virologic failure in the P011 study comparing islatravir plus DOR vs DOR/3TC/TDF in treatment-naive adults
  • A study evaluating the lenacapavir pharmacokinetic profile
  • Results from the HPTN 083 trial investigating the efficacy and safety of long-acting injectable cabotegravir vs daily oral TDF/FTC for PrEP in MSM and TGW

Content based on a CME program supported by independent educational grants from Gilead Sciences, Merck Sharp & Dohme Corp., and ViiV Healthcare.

Link to full program: https://www.clinicaloptions.com/hiv/conference-coverage/aids-2020


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Information on this Educational Activity


Chloe Orkin, MBChB, FRCP, MD

Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD, has disclosed that she has received funds for research support, consulting fees, and fees for non-CME/CE services from Gilead Sciences, GlaxoSmithKline, Janssen, MSD, and ViiV.


Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.